This report analyzes the worldwide markets for Antibiotics in US$ Billion. The Major product segments Analyzed are Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 205 companies including many key and niche players worldwide such as Abbott Laboratories, MiddleBrook Pharmaceuticals, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook・Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., Toyama Chemical Co., Ltd., and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

TABLE OF CONTENTS:

ANTIBIOTICS			MCP-1705
A GLOBAL STRATEGIC BUSINESS REPORT


                                              CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-2
      Product Definitions and Scope of Study                            I-3
       Penicillin                                                       I-3
       Cephalosporins                                                   I-4
       Macrolides                                                       I-4
       Quinolones                                                       I-4
       Carbapenems                                                      I-4
       Other Antibiotics                                                I-4
        Aminoglycosides                                                 I-4
        Tetracyclines                                                   I-4
        Sulfonamides                                                    I-4
        Mupirocin                                                       I-5
        Glycopeptides                                                   I-5
        Synercid                                                        I-5
        Oxazolidinones                                                  I-5
         Linezolid                                                      I-5


 II. EXECUTIVE SUMMARY

  1. Industry Overview                                                  II-1
      Antibiotic Resistance and Generic Competition to Impact Long
       Term Growth                                                      II-1
      Current & Future Analysis                                         II-1

  2. Market Dynamics                                                    II-2
      Anti-Bacterials Segment Drives Global Anti-Infectives  Market     II-2
      Antibiotic Resistance - A Primary Growth Inhibitor                II-2
       Antibiotic-Resistant Bacteria by Type                            II-2
      Patent Expiries Commoditize Antibiotics                           II-3
      Patent Expiries of Leading Drugs in the Recent Past,  Current,
       and Future                                                       II-3
      Anti-MRSA Antibiotics Find Their Way   .                          II-3
       Table 1: Estimated Revenues Generated by Leading MRSA
       Antibiotic Drugs in 2005 (includes corresponding Graph/Chart)    II-4
      Key Antibiotics in Pipeline                                       II-4

  3. Competition                                                        II-5
      Highly Competitive Market                                         II-5
       Table 2: Leading Players in the Worldwide Antibiotics Market
       (2006): Percentage Breakdown by Value Sales for Pfizer, Glaxo
       Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott,
       Wyeth, and Others (includes corresponding Graph/Chart)           II-5
      GlaxoSmithKline - The Undisputed Leader of Penicillin Market      II-5
       Table 3: Worldwide Leading Antibiotics within Penicillin
       Class (2005 & 2006): Percentage Breakdown by Value for
       Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes
       corresponding Graph/Chart)                                       II-6
      GlaxoSmithKline Leads Cephalosporin Market                        II-6
       Table 4: Worldwide Leading Antibiotics within Cephalosporin
       Class (2005 & 2006): Percentage Breakdown by Value for
       Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil,
       Cefzon, Flumarin, and Others (includes corresponding
       Graph/Chart)                                                     II-6
      Pfizer Dominates Macrolides Market                                II-7
       Table 5: Worldwide Leading Antibiotics within Macrolide Class
       (2005 & 2006): Percentage Breakdown by Value for Zithromax,
       Klaricid/Biaxin, Ketek, and Others (includes corresponding
       Graph/Chart)                                                     II-7
      Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic        II-7
       Table 6: Worldwide Leading Antibiotics within Quinolone Class
       (2005 & 2006): Percentage Breakdown by Value for
       Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and
       Others (includes corresponding Graph/Chart)                      II-7
      Merck Rules Carbapenems Market                                    II-8
       Table 7: Worldwide Leading Antibiotics within Carbapenem
       Class (2005 & 2006): Percentage Breakdown by Value for
       Primaxin, Merrem, Invanz, and Others (includes corresponding
       Graph/Chart)                                                     II-8

  4. Product Overview                                                   II-9
      Antibiotics - An Introduction                                     II-9
      Antibiotic Resistance                                             II-9
      ß -Lactams                                                        II-10
      Classification of Antibiotics                                     II-11
      Key Milestones in Antibiotic Development                          II-11
      Antibiotic Types                                                  II-11
       Penicillin                                                       II-11
        History                                                         II-11
        About the Drug                                                  II-12
       Cephalosporins                                                   II-12
        Treatment                                                       II-12
        Effects of the Drug                                             II-13
       Macrolides                                                       II-13
        Treatment                                                       II-13
       Quinolones                                                       II-13
       Carbapenems                                                      II-14
       Other Antibiotics                                                II-14
        Aminoglycosides                                                 II-14
         Treatment                                                      II-14
         Effects of the Drug                                            II-15
        Tetracyclines                                                   II-15
         Treatment                                                      II-15
         Effects of the Drug                                            II-16
        Sulfonamides                                                    II-16
         Treatment                                                      II-16
         Effects of the Drug                                            II-17
        Mupirocin                                                       II-17
        Glycopeptides                                                   II-17
        Synercid                                                        II-17
        Oxazolidinones                                                  II-18
         Linezolid                                                      II-18

  5. Research Findings                                                  II-19
      Cephalosporins Effective when Compared to Penicillin              II-19
      FDA Bans Baytril Antibiotic for Chickens                          II-19
      Erythromycin Along with Some Specific Drugs Increase Risk of
       Sudden Death                                                     II-19
      Rise in Usage of Quinolones for Urinary Tract Infections Leads
       to Drug Resistance                                               II-19

  6. FDA Approvals/Patents                                              II-20
      MiddleBrook Obtains NDA Approval for MOXATAG                     II-20
      J&JPRD Seeks FDA Approval for Doripenem Antibiotic                II-20
      J&JPRD Seeks FDA Approval for Investigational  Antibiotic,
       Ceftobiprole                                                     II-20
      GSK Receives Approval for ALTARGO in Europe                      II-20
      APL Receives FDA Approval for Cefpodoxime Proxetil                II-21
      Cubist Receives Approval to Market CUBICIN in Canada              II-21
      Cubist Obtains Approval to Market CUBICIN for  Added
       Indications in EU                                                II-21
      Cubist Gains Approval for CUBICIN in Taiwan and  South Korea      II-21
      Cethromycin Achieves FDA's Orphan Drug Designation                II-21
      FDA Approves Wockhardt's Cefotaxime Injection                     II-22
      FDA Approves Doxycycline Tablets                                  II-22
      FDA Approves Clarithromycin                                       II-22
      FDA Approves Doxycycline Tablets For The US Market                II-22
      Johnson & Johnson Applies Doripenem For FDA Approval              II-22
      FDA Certifies Antibioticos do Brasil's Plant                      II-22
      FDA Certifies ANDA For Cefdinir Capsules                          II-22
      US FDA Approves Teva's Cefprozil Tablets                          II-23
      FDA Certifies ANDA for Cephalexin Capsules                        II-23
      American Pharmaceutical Partners Receives FDA Approvals for
       Ceftriaxone for Injection, USP                                   II-23
      Advancis's Keflex Receives FDA Approval                           II-23
      Wockhardt Gains Marketing Approval for Cefuroxime axetil in
       the US                                                           II-23
      Wyeth's Mylotarq Receives Government's Approval                   II-23
      FDA Approves Generic Version of Zithromax                         II-24
      Pfizer Wins FDA Approval for Zmax                                II-24
      Venus Remedies Files Second PCT for New Cephalosporins            II-24
      Falcon Gains US FDA Approval for its Generic Anti-Infective
       Solution                                                         II-24
      Cadilla Receives FDA Approval to Market Clindamycin               II-25

  7. Recent Industry Activity                                           II-26
      3i to Buy Alpharma Unit                                           II-26
      NCPC to Acquire Stake in DSM's Antibiotics Division               II-26
      ULL Establishes New Antibiotics Unit in Himachal  Pradesh         II-26
      Biocat to Expand Presence in the Indian Market                    II-26
      PRWT Acquires Cherokee Chemical Unit from Merck                   II-26
      CSPC Joins Hands with Indonesian Firms                            II-27
      Nisshin-Kyorin to Merge with Kyorin Pharmaceutical                II-27
      Schering-Plough Acquires Organon BioSciences                      II-27
      GSK & Anacor Partner for Boron Chemistry-Based  Antibiotics
       and Antivirals                                                   II-27
      Iroko Bags Canadian Rights to Vancocin                           II-28
      Cubist Licenses CUBICIN Rights to Merck                           II-28
      Sagent Partners with Astral to Develop Injectable  Antibiotics    II-28
      MR Healthcare to Manufacture New Antibiotics & Medicines          II-28
      Livzon Synthetic to Acquire Antibiotic Intermediate  from Jiaozuo II-29
      C&O Pharmaceutical to Distribute Meiact in China                  II-29
      Bioton Signs Deal to Market Antibiotics in Russia                 II-29
      Toyama Gains Marketing Approval for Geninax  in Japan            II-29
      Forest Laboratories Acquires Cerexa                               II-29
      Oscient Modifies Licensing Agreement With LG Life Sciences        II-29
      Orchid Sign Licensing & Distribution Pact With Actavis            II-30
      Forest Laboratories Revokes Partnership With Replidyne            II-30
      SRI and Blanca Collaborate To Develop & Test Carbacephem          II-30
      AstraZeneca To Expand Research Center For Antibiotics             II-30
      Jade Pharmaceutical Begins Levofloxacin's Production in China     II-30
      Reyoung To Start Antibiotic Production At New Facility            II-31
      Toyama Begins T-705 Clinical Trials                               II-31
      SmPC For Sanofi-Aventis' Ketek Updated                           II-31
      Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic
       Tablets in France                                                II-31
      Antibiotice Plans To Infuse Funds For Antibiotics Production      II-31
      UAE Approves Pfizer's Zithromax SD                                II-31
      Premier Takes Over Cereplex                                       II-31
      Laboratorios Roemmers Acquires Argentine Pharmaceutical's
       Business                                                         II-32
      Ranbaxy Adds Be-Tabs                                              II-32
      AstraZeneca Purchases Vancocin From Eli Lilly                    II-32
      Ranbaxy Laboratories Limited Acquires Ethimed NV                  II-32
      Ranbaxy Laboratories Limited Acquires Terapia SA                  II-32
      Ranbaxy Italia Acquires Allen Generic Business of GlaxoSmithKline II-33
      Connetics Acquires Sales Organization of PediaMed                 II-33
      Wyeth Increases Stake in Wyeth KK to 80%                          II-33
      Sankyo Pharma, Daiichi Medical Research and Daiichi
       Pharmaceutical Merge                                             II-34
      Merck & Co. and Paratek Sign Development & License Pact           II-34
      Wakunga and Rib-X Sign Licensing Pact                             II-34
      Pfizer Settles Infringement Lawsuit With Teva                     II-34
      Astellas Extends Agreement With Theravance                        II-34
      Astellas and Theravance Sign Collaboration Agreement              II-35
      Cubist and AstraZeneca Sign License Pact                          II-35
      Astellas Pharma and Sanofi-Aventis Revoke  Marketing Pact         II-35
      Achaogen Bags Licensing Agreement from Isis                       II-35
      Pfizer Bags Rights from Oscient to Market Antibiotic in Mexico    II-35
       Replidyne Enters into Licensing Agreement with Forest
        Laboratories                                                    II-35
      Toyama Chemical Co Ltd Enters into Licensing Agreement with
       Astellas Pharma                                                  II-36
       AVAS' Majority Stake To Be Sold                                  II-36
      NIH Grants US$3 Million To PolyMedix For  Antibiotics             II-36
      Wyeth's Tygacil Achieves European Approval                        II-36
      Chiron's Cubicin Receives Marketing Grant In The EU              II-37
      Vietnam Bans Antibiotics In Aquaculture                           II-37
      Sance Pharmaceuticals Establishes Sance Laboratories              II-37
      Caps Holdings Plans to Re-enter Penicillin Market                 II-37
      Alkem Establishes Sterile Cephalosporin Unit                      II-37
      Novartis Completes Chiron Acquisition                             II-37
      Toyama Submits New Drug Application For Quinolone Antibiotic
       Compound                                                         II-37
      China Pharma Receives GMP Certification For Cephalosporin
       Antibiotic Production                                            II-38
      Venus Remedies Files For FDC Approval                             II-38
      Sankyo Acquires rival Daiichi Pharmaceutical for US$ 7 Billion    II-38
      Daiichi Pharmaceutical Takes Over Daiichi Suntory Pharma          II-38
      Pfizer Acquires Idun Pharmaceuticals                              II-38
      Pfizer Acquires Vicuron Pharmaceuticals                           II-39
      Pfizer Acquires Bioren                                            II-39
      Novartis Acquires Eon Labs                                        II-39
      Kyorin Pharmaceutical Acquires Stake in Toyo Pharmar              II-40
      Targanta Acquires InterMune's Late-Stage Antibiotic               II-40
      Novartis Acquires Hexal                                           II-40
      TB Alliance and Bayer Partner in Clinical Trials                  II-41
      SBC Communications Enters into Agreement with Pfizer for
       Managed Voice Services                                           II-41
      Vicuron Extends Oral Antibiotics Development  Agreement With
       Pfizer                                                           II-42
      Orchid Chemicals Signs Distribution Agreement with Mayne Pharma   II-42
      Cubist Pharmaceuticals Inks Agreement with ACS Dobfar             II-42
      Orchid Chemicals Inks Marketing Agreement with Alpharma           II-42
      Lupin and DSM Anti-Infectives Sign Agreement to  Market
       Cephalosporins                                                   II-42
      Ranbaxy to Market P&G's Generic Drug                              II-43
      Nectar Expands Capacity                                           II-43
      Novartis Establishes Novartis Holding Japan                       II-43
      Sun Pharma Acquires Phlox Pharma                                  II-43
      Kyorin Takes Over ActivX                                          II-43
      Advancis Acquires Lilly's Keflex Brand                            II-43
      Enanta Enters into Partnership with Shionogi & Co.                II-44
      Toyama Signs Collaborative Agreement with Glaxo to Develop
       Antibacterial Agents                                             II-44
      Enanta and Shionogi Ink an Agreement to Market EP- 013420         II-45
      Orchid Inks Agreement with Apotex to Market Generic Antibiotics   II-45
      Toyama Signs Licensing Agreement for TN-3262a with Dong-A         II-45
      Toyama Inks License Agreement with Schering for T-3811            II-45
      Shionogi Wins Rights to Market Cedax in the US                    II-46
      Connetics Enters Acne Market                                      II-46

  8. Product Innovations/Introductions                                  II-47
      MIT Scientists Develop a New Antibiotic,  Rhodostreptomycin       II-47
      Watson Pharma Introduces Biaxin XL's Generic Version              II-47
      Toyama Launches New Garenoxacin Quinolone Antibiotic              II-47
      Wockhardt to Introduce Cefprozil in the US                        II-47
      MSD India Launches Invanza in India                               II-47
      Orchid Chemicals to Introduce Three New Drugs in the US           II-48
      DUSA Pharmaceuticals Releases ClindaReach                        II-48
      Mylan Releases Cipro's Generic Version                            II-48
      Macrolide Antibiotic Developed In the US                          II-48
      University of Michigan Devises NMR Spectroscopy For Antibiotics   II-48
      Glycopeptide-Cephalosporin Antibiotics Developed In The US        II-48
      Neosil Tests NEO 101 Antibiotic                                   II-48
      New Antibiotic Developed By Canadian Inventors                    II-49
      Abbott Canada Releases FACTIVE Antibiotic Tablets In Canada      II-49
      Pencillin Binding Protein Found In Japan                          II-49
      Venus Remedies Releases Mucomelt-Forte                            II-49
      Baxter Launches Injectable Antibiotic, Zithromax                  II-49
      Advancis Releases Keflex (750mg) Capsules                         II-49
      Researchers Develop Antibiotic For MRSA                           II-50
      Wyeth Releases Tygacil In The UK                                  II-50
      Nihon Pharmaceutical Releases Clarithomycin  Antibiotic           II-50
      Daiichi Sankyo Engages In Quinolone Antibiotic Development        II-50
      Shionogi Commercializes Finibax                                   II-50
      Sandoz and Nomura Phase4 Ventures Launch Nabriva Therapeutics
       Forschungs GmbH                                                  II-50
      Lilly's Investigational Cancer Agent Reaches Phase III
       Clinical Trial                                                   II-50
      Idemitsu Technofine Launches Antibacterial Product                II-51
      Galleon Develops Oral Aminoglycoside Antibiotic                   II-51
      Advancis Introduces Keflex Powder in the US                      II-51
      Skin Test for Penicillin Comes Back into the Market               II-51
      Cubist Introduces New Registry Program                            II-52
      Idemitsu Technofine Launches Antibacterial Product                II-52

  9. Focus on Select Global Players                                     II-53
      Abbott Laboratories (USA)                                         II-53
      MiddleBrook Pharmaceuticals, Inc. (USA)                          II-53
      Bayer HealthCare AG (Germany)                                     II-53
      Bristol-Myers Squibb Co. (USA)                                    II-54
      Cubist Pharmaceuticals, Inc. (USA)                                II-54
      Daiichi Sankyo Company, Limited (Japan)                           II-54
      Eli Lilly and Co. (USA)                                           II-55
      GlaxoSmithKline Plc (UK)                                          II-56
      Johnson & Johnson (USA)                                           II-56
      Kyorin Pharmaceutical Co., Ltd. (Japan)                           II-57
      LG Life Sciences Limited (Korea)                                  II-57
      MiddleBrook Pharmaceuticals, Inc.  (USA)                         II-58
      Novartis AG (Switzerland)                                         II-58
      Pfizer Inc. (USA)                                                 II-59
      Pliva d.d. (Croatia)                                              II-59
      Roche (Switzerland)                                               II-60
      Sanofi-Aventis SA (France)                                        II-60
      Takeda Pharmaceutical Company, Ltd. (Japan)                       II-60
      Toyama Chemical Co., Ltd. (Japan)                                 II-61
      Wyeth Pharmaceuticals, Inc. (USA)                                 II-61

  10. Global Market Perspective                                         II-63
      Table 8: World Recent Past, Current & Future Analysis for
      Antibiotics by Geographic Region - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), and Rest of World Markets
      Independently Analyzed with Annual Sales in US$ Million for
      Years 2000 through 2010 (includes corresponding Graph/Chart)      II-63

      Table 9: World Long-term Projections for Antibiotics by
      Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), and Rest of World Markets Independently
      Analyzed with Annual Sales in US$ Million for Years 2011
      through 2015 (includes corresponding Graph/Chart)                 II-64

      Table 10: World 10-Year Perspective for Antibiotics by
      Geographic Region - Percentage Breakdown of  Dollar Sales for
      US, Canada, Japan, Europe,  Asia-Pacific (excluding Japan),
      and Rest of World  Markets for Years 2003, 2008 & 2012
      (includes  corresponding Graph/Chart)                             II-65

      Table 11: World Recent Past, Current & Future Analysis for
      Penicillin by Geographic Region - US, Canada, Japan,  Europe,
      Asia-Pacific (excluding Japan), and Rest of World Markets
      Independently Analyzed with Annual Sales in US$ Million for
      Years 2000 through 2010 (includes  corresponding Graph/Chart)     II-66

      Table 12: World Long-term Projections for Penicillin by
      Geographic Region - US, Canada, Japan, Europe,  Asia-Pacific
      (excluding Japan), and Rest of World Markets Independently
      Analyzed with Annual Sales in US$ Million  for Years 2011
      through 2015 (includes  corresponding Graph/Chart)                II-67

      Table 13: World 10-Year Perspective for Penicillin by
      Geographic Region - Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
      Rest of World Markets for Years  2003, 2008 & 2012 (includes
      corresponding Graph/Chart)                                        II-68

      Table 14: World Recent Past, Current & Future Analysis for
      Cephalosporin by Geographic Region - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), and Rest of World
      Markets Independently Analyzed with Annual Sales in US$
      Million for Years 2000 through 2010 (includes corresponding
      Graph/Chart)                                                      II-69

      Table 15: World Long-term Projections for Cephalosporin by
      Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), and Rest of World Markets Independently
      Analyzed with Annual Sales in US$ Million for Years 2011
      through 2015 (includes corresponding Graph/Chart)                 II-70

      Table 16: World 10-Year Perspective for Cephalosporin by
      Geographic Region - Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
      Rest of World Markets for Years  2003, 2008 & 2012 (includes
      corresponding Graph/Chart)                                        II-71

      Table 17: World Recent Past, Current & Future Analysis for
      Macrolides by Geographic Region - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), and Rest of World Markets
      Independently Analyzed with Annual Sales in US$ Million for
      Years 2000 through 2010 (includes corresponding Graph/Chart)      II-72

      Table 18: World Long-term Projections for Macrolides by
      Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), and Rest of World Markets Independently
      Analyzed with Annual Sales in US$ Million for Years 2011
      through 2015 (includes corresponding Graph/Chart)                 II-73

      Table 19: World 10-Year Perspective for Macrolides by
      Geographic Region - Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
      Rest of World Markets for Years 2003, 2008 & 2012 (includes
      corresponding Graph/Chart)                                        II-74

      Table 20: World Recent Past, Current & Future Analysis for
      Quinolones by Geographic Region - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), and Rest of World Markets
      Independently Analyzed with Annual Sales in US$ Million for
      Years 2000 through 2010 (includes corresponding Graph/Chart)      II-75

      Table 21: World Long-term Projections for Quinolones by
      Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), and Rest of World Markets Independently
      Analyzed with Annual Sales in US$ Million for Years 2011
      through 2015 (includes corresponding Graph/Chart)                 II-76

      Table 22: World 10-Year Perspective for Quinolones by
      Geographic Region - Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
      Rest of World Markets for Years  2003, 2008 & 2012 (includes
      corresponding Graph/Chart)                                        II-77

      Table 23: World Recent Past, Current & Future Analysis for
      Carbapenems by Geographic Region - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), and Rest of World Markets
      Independently Analyzed with Annual Sales in US$ Million for
      Years 2000 through 2010 (includes corresponding Graph/Chart)      II-78

      Table 24: World Long-term Projections for Carbapenems by
      Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), and Rest of World Markets Independently
      Analyzed with Annual Sales in US$ Million for Years 2011
      through 2015 (includes corresponding Graph/Chart)                 II-79

      Table 25: World 10-Year Perspective for Carbapenems by
      Geographic Region - Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
      Rest of World Markets for Years  2003, 2008 & 2012 (includes
      corresponding Graph/Chart)                                        II-80

      Table 26: World Recent Past, Current & Future Analysis for
      Other Antibiotics by Geographic Region - US,  Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), and Rest of World
      Markets Independently Analyzed with Annual Sales in US$
      Million for Years 2000 through 2010 (includes corresponding
      Graph/Chart)                                                      II-81

      Table 27: World Long-term Projectionsfor Other Antibiotics by
      Geographic Region - US, Canada, Jap an, Europe, Asia- Pacific
      (excluding Japan), and Rest of World Markets Independently
      Analyzed with Annual Sales in US$ Million for Years 2011
      through 2015 (includes corresponding Graph/Chart)                 II-82

      Table 28: World 10-Year Perspective for Other Antibiotics by
      Geographic Region - Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
      Rest of World Markets for Years 2003, 2008 & 2012 (includes
      corresponding Graph/Chart)                                        II-83


III. MARKET

  1. The United States                                                  III-1
      A.Market Analysis                                                 III-1
        Current and Future Analysis                                     III-1
          Antibiotics Approved Between 2000 and 2005 in the United
           States                                                       III-1
         Competition                                                    III-1
          Table 29: Leading Players in the US Antibiotics Market
          (2006): Percentage Breakdown by Value Sales for Pfizer,
          Johnson & Johnson, GlaxoSmithKline, Abbott, and Others
          (includes corresponding Graph/Chart)                          III-2
        Strategic Corporate Developments                                III-2
        Product Introductions/Innovations                               III-10
        FDA Approvals / Patents                                         III-12
        Focus on Select Players                                         III-16
      B.Market Analytics                                                III-20
        Table 30: US Recent Past, Current & Future Analysis for
        Antibiotics by Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales  in US$
        Million for Years 2000 through 2010 (includes corresponding
        Graph/Chart)                                                    III-20

        Table 31: US Long-term Projections for Antibiotics by
        Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        MarketsIndependently Analyzed with  Annual Sales in US$
        Million for Years 2011  through 2015 (includes corresponding
        Graph/Chart)                                                    III-21

        Table 32: US 10-Year Perspective for Antibiotics by Product
        Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides, Quinolones,
        Carbapenems and Other Antibiotics Markets for  2003, 2008 &
        2012 (includes corresponding  Graph/Chart)                      III-22

  2. Canada                                                             III-23
       Market Analysis                                                  III-23
        Current And Future Analysis                                     III-23
        Strategic Corporate Developments                                III-23
        Product Introductions/Innovations                               III-24
        Table 33: Canadian Recent Past, Current & Future Analysis
        for Antibiotics by Product Segment - Penicillin,
        Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
        Antibiotics Markets Independently Analyzed with Annual Sales
        in US$ Million for Years 2000 through 2010 (includes
        corresponding Graph/Chart)                                      III-25

        Table 34: Canadian Long-term Projections for Antibiotics by
        Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2011 through 2015 (includes corresponding
        Graph/Chart)                                                    III-26

        Table 35: Canadian 10-Year Perspective for Antibiotics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides,Quinolones,
        Carbapenems and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-27

  3. Japan                                                              III-28
      A.Market Analysis                                                 III-28
        Current and Future Analysis                                     III-28
        Strategic Corporate Developments                                III-28
        Product Introductions/Innovations                               III-31
        Focus on Select Players                                         III-32
      B.Market Analytics                                                III-35
        Table 36: Japanese Recent Past, Current & Future Analysis
        for Antibiotics by Product Segment -  Penicillin,
        Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
        Antibiotics Markets  Independently Analyzed with Annual
        Sales  in US$ Million for Years 2000 through 2010  (includes
        corresponding Graph/Chart)                                      III-35

        Table 37: Japanese Long-term Projections for Antibiotics by
        Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2011 through 2015 (includes corresponding
        Graph/Chart)                                                    III-36

        Table 38: Japanese 10-Year Perspective for Antibiotics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides, Quinolones,
        Carbapenems and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-37

  4. Europe                                                             III-38
      A.Market Analysis                                                 III-38
        Current and Future Analysis                                     III-38
        Strategic Corporate Developments                                III-38
      B.Market Analytics                                                III-40
        Table 39: European Recent Past, Current & Future Analysis
        for Antibiotics by Geographic Region - France, Germany,
        Italy, UK, Spain, and Rest of Europe Markets Independently
        Analyzed with Annual Sales in  US$ Million for Years 2000
        through 2010  (includes corresponding Graph/Chart)              III-40

        Table 40: European Long-term Projections for Antibiotics by
        Geographic Region - France, Germany, Italy, UK, Spain, and
        Rest of Europe Markets Independently Analyzed with Annual
        Sales in US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-41

        Table 41: European Recent Past, Current & Future Analysis
        for Antibiotics by Product Segment - Penicillin,
        Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other
        Antibiotics Markets Independently Analyzed with Annual Sales
        in US$ Million for Years 2000 through 2010 (includes
        corresponding Graph/Chart)                                      III-42

        Table 42: European Long-term Projections for  Antibiotics by
        Product Segment - Penicillin,  Cephalosporin,
        Macrolides,Quinolones, Carbapenems, and Other Antibiotics
        Markets Independently Analyzed  with Annual Sales in US$
        Million for Years 2011  through 2015 (includes corresponding
        Graph/Chart)                                                    III-43

        Table 43: European 10-Year Perspective for Antibiotics by
        Geographic Region - Percentage Breakdown of Dollar Sales for
        France, Germany, Italy, UK, Spain, and Rest of Europe
        Markets for 2003, 2008 & 2012 (includes corresponding
        Graph/Chart)                                                    III-44

        Table 44: European 10-Year Perspective for Antibiotics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides, Quinolones,
        Carbapenems, and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-45

  4a. France                                                            III-46
      A.Market Analysis                                                 III-46
        Current and Future Analysis                                     III-46
        Trends                                                          III-46
         Over Consumption of Antibiotics - Cause of Concern             III-46
        Strategic Corporate Developments                                III-47
        Sanofi-Aventis SA - A Key Player                                III-47
      B.Market Analytics                                                III-48
        Table 45: French Recent Past, Current & Future Analysis for
        Antibiotics by Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2000 through 2010 (includes corresponding
        Graph/Chart)                                                    III-48

        Table 46: French Long-term Projections for Antibiotics by
        Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2011 through 2015 (includes corresponding
        Graph/Chart)                                                    III-49

        Table 47: French 10-Year Perspective for Antibiotics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides, Quinolones,
        Carbapenems and Other Antibiotics Markets for2003, 2008 &
        2012  (includes corresponding Graph/Chart)                      III-50

  4b. Germany                                                           III-51
      A.Market Analysis                                                 III-51
        Current and Future Analysis                                     III-51
        Strategic Corporate Developments                                III-51
        Bayer HealthCare AG - A Key Player                              III-52
      B.Market Analytics                                                III-53
        Table 48: German Recent Past, Current & Future Analysis for
        Antibiotics by Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2000 through 2010 (includes corresponding
        Graph/Chart)                                                    III-53

        Table 49: German Long-term Projections for Antibiotics by
        Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other  Antibiotics
        Markets Independently Analyzed with  Annual Sales in US$
        Million for Years 2011 through  2015 (includes corresponding
        Graph/Chart)                                                    III-54

        Table 50: German 10-Year Perspective for Antibiotics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides,Quinolones,
        Carbapenems and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-55

  4c. Italy                                                             III-56
      A.Market Analysis                                                 III-56
        Current and Future Analysis                                     III-56
        Corporate Development                                           III-56
      B.Market Analytics                                                III-57
        Table 51: Italian Recent Past, Current & Future Analysis for
        Antibiotics by Product Segment - Penicillin, Cephalosporin,
        Macrolides, Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2000 through  2010 (includes corresponding
        Graph/Chart)                                                    III-57

        Table 52: Italian Long-term Projections for Antibiotics by
        Product Segment - Penicillin, Cephalosporin, Macrolides,
        Quinolones, Carbapenems and Other Antibiotics Markets
        Independently Analyzed with Annual Sales in US$ Million for
        Years 2011 through 2015 (includes corresponding Graph/Chart)    III-58

        Table 53: Italian 10-Year Perspective for Antibiotics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides,Quinolones,
        Carbapenems and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-59

  4d. The United Kingdom                                                III-60
       Market Analysis                                                  III-60
        Current And Future Analysis                                     III-60
        Product Introduction                                            III-60
        GlaxoSmithKline Plc - A Key Player                              III-60
        Table 54: UK Recent Past, Current & Future Analysis for
        Antibiotics by Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales  in US$
        Million for Years 2000 through 2010  (includes corresponding
        Graph/Chart)                                                    III-61

        Table 55: UK Long-term Projections for Antibiotics by
        Product Segment - Penicillin, Cephalosporin, acrolides,
        Quinolones, Carbapenems and Other Antibiotics Markets
        Independently Analyzed with Annual Sales in US$ Million for
        Years 2011 through 2015 (includes  corresponding
        Graph/Chart)                                                    III-62

        Table 56: UK 10-Year Perspective for Antibiotics by Product
        Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides, Quinolones,
        Carbapenems and Other Antibiotics Markets for2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-63

  4e. Spain                                                             III-64
       Market Analysis                                                  III-64
        Table 57: Spanish Recent Past, Current & Future Analysis for
        Antibiotics by Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2000 through 2010 (includes corresponding
        Graph/Chart)                                                    III-64

        Table 58: Spanish Long-term Projections for Antibiotics by
        Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2011 through 2015 (includes corresponding
        Graph/Chart)                                                    III-65

        Table 59: Spanish 10-Year Perspective for Antibiotics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Penicillin, Cephalosporin, Macrolides, Quinolones,
        Carbapenems and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-66

  4f. Rest of Europe                                                    III-67
      A.Market Analysis                                                 III-67
        Current and Future Analysis                                     III-67
        Strategic Corporate Developments                                III-67
        Product Launch                                                  III-69
        Focus on Select Players                                         III-69
      B.Market Analytics                                                III-71
        Table 60: Rest of Europe Recent Past, Current & Future
        Analysis for Antibiotics by Product Segment - Penicillin,
        Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
        Antibiotics Markets Independently Analyzed with Annual Sales
        in US$ Million for Years 2000 through 2010 (includes
        corresponding Graph/Chart)                                      III-71

        Table 61: Rest of Europe Long-term Projections for
        Antibiotics by Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2011 through 2015  (includes corresponding
        Graph/Chart)                                                    III-72

        Table 62: Rest of Europe 10-Year Perspective for Antibiotics
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Penicillin, Cephalosporin, Macrolides,Quinolones,
        Carbapenems and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-73

  5. Asia-Pacific                                                       III-74
      A.Market Analysis                                                 III-74
        Current and Future Analysis                                     III-74
        India                                                           III-74
         Rising Prices of Penicillin G to Affect Antibiotics
          Production                                                    III-74
        Strategic Corporate Developments                                III-74
        Product Introduction                                            III-79
        FDA Approvals / Patents                                         III-79
        Focus on Select Players                                         III-79
      B.Market Analytics                                                III-81
        Table 63: Asia-Pacific Recent Past, Current & Future
        Analysis for Antibiotics by Product Segment - Penicillin,
        Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
        Antibiotics Markets Independently Analyzed with Annual Sales
        in US$ Million for Years 2000 through 2010 (includes
        corresponding Graph/Chart)                                      III-81

        Table 64: Asia-Pacific Long-term Projections for Antibiotics
        by Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2011 through 2015 (includes corresponding
        Graph/Chart)                                                    III-82

        Table 65: Asia-Pacific 10-Year Perspective for Antibiotics
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Penicillin, Cephalosporin, Macrolides, Quinolones,
        Carbapenems and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes  corresponding Graph/Chart)                      III-83

  6. Rest of World                                                      III-84
      A.Market Analysis                                                 III-84
        Current and Future Analysis                                     III-84
        Strategic Corporate Developments                                III-84
      B.Market Analytics                                                III-85
        Table 66: Rest of World Recent Past, Current & Future
        Analysis for Antibiotics by Product Segment - Penicillin,
        Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
        Antibiotics Markets Independently Analyzed with Annual Sales
        in US$ Million for Years 2000 through 2010 (includes
        corresponding Graph/Chart)                                      III-85

        Table 67: Rest of World Long-term Projections for
        Antibiotics by Product Segment - Penicillin, Cephalosporin,
        Macrolides,Quinolones, Carbapenems and Other Antibiotics
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2011 through 2015 (includes corresponding
        Graph/Chart)                                                    III-86

        Table 68: Rest of World 10-Year Perspective for Antibiotics
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Penicillin, Cephalosporin, Macrolides,Quinolones,
        Carbapenems and Other Antibiotics Markets for 2003, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-87


 IV. COMPETITIVE LANDSCAPE